Latest Data From Our Hair Cell Therapy Human Trials
25th January 2009
ICX-TRC is an autologous (donor source is same as recipient) hair regeneration therapy intended for the treatment of male pattern baldness and female hair loss. Drs Farjo are the Principal Investigators in this trial on behalf of Manchester-based Intercytex Group plcsince 2003. Success will promise potentially unlimited supply of donor hair for patients.
Latest Update released on September 18th, 2008 on Phase II of the clinical trial:
We have now completed the treatment phase of our Phase II study designed to optimise the delivery of the DP cells.
In this study, hair counts are obtained by shaving and photographing a small section of scalp, injecting it and then applying a specialised image analysis system to provide a total hair count. All 19 subjects in the trial have now been treated using a range of injection and scalp pre-stimulation techniques; the first 6 subjects were injected without stimulation of the scalp. In the remaining 13 the resident hair producing (epithelial) cells were stimulated at the time of delivery of the DP cells.
Two sub-groups were each injected with autologous DP cells using different delivery techniques. The first group focussed on delivery of the hair inductive DP cells, and in the second group resident hair producing (epithelial) cells were also stimulated at the time of delivery.
At 24 weeks the results are as follows: More information is also published on www.intercytex.com
Of the five subjects who received DP cells with no pre-stimulation of the scalp three (60%) showed an increase in hair counts
Of the nine subjects who received DP cells with pre-stimulation of the scalp eight (89%) showed an increase in hair counts
Two subjects were not evaluable at this time-point
At the end of Q1 next year when the trial has concluded, photographic data will be analysed from a much larger area of treated scalp on all subjects at 12 months.
Currently three subjects have been lost to follow up.